Y Intercept Hong Kong Ltd Invests $99,000 in Verrica Pharmaceuticals Inc. $VRCA

Y Intercept Hong Kong Ltd acquired a new position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) in the second quarter, Holdings Channel.com reports. The fund acquired 186,955 shares of the company’s stock, valued at approximately $99,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in VRCA. AQR Capital Management LLC raised its stake in Verrica Pharmaceuticals by 306.7% in the first quarter. AQR Capital Management LLC now owns 58,711 shares of the company’s stock valued at $26,000 after buying an additional 44,275 shares during the last quarter. Invesco Ltd. grew its stake in shares of Verrica Pharmaceuticals by 64.8% during the first quarter. Invesco Ltd. now owns 74,388 shares of the company’s stock worth $33,000 after acquiring an additional 29,256 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Verrica Pharmaceuticals by 127.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 99,505 shares of the company’s stock valued at $44,000 after acquiring an additional 55,852 shares in the last quarter. Kovitz Investment Group Partners LLC acquired a new position in shares of Verrica Pharmaceuticals during the first quarter valued at about $45,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Verrica Pharmaceuticals by 23.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company’s stock valued at $61,000 after purchasing an additional 26,308 shares during the last quarter. 42.45% of the stock is currently owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Stock Performance

Verrica Pharmaceuticals stock opened at $3.46 on Monday. The business’s 50-day simple moving average is $4.31 and its two-hundred day simple moving average is $5.48. The company has a market cap of $32.70 million, a PE ratio of -0.42 and a beta of 1.71. Verrica Pharmaceuticals Inc. has a fifty-two week low of $3.28 and a fifty-two week high of $13.60.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings data on Tuesday, August 12th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.72. The firm had revenue of $12.70 million during the quarter, compared to analysts’ expectations of $4.37 million. As a group, analysts predict that Verrica Pharmaceuticals Inc. will post -1.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Verrica Pharmaceuticals has a consensus rating of “Reduce”.

Verrica Pharmaceuticals Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.